A detailed history of Nuveen Asset Management, LLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 169,549 shares of FULC stock, worth $506,951. This represents 0.0% of its overall portfolio holdings.

Number of Shares
169,549
Previous 169,549 -0.0%
Holding current value
$506,951
Previous $1.05 Million 42.44%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$5.98 - $9.31 $1.01 Million - $1.58 Million
169,549 New
169,549 $1.05 Million
Q1 2023

May 15, 2023

BUY
$2.83 - $13.99 $99,083 - $489,817
35,012 Added 13.8%
288,737 $822,000
Q4 2022

Feb 14, 2023

BUY
$5.01 - $8.35 $478,550 - $797,583
95,519 Added 60.38%
253,725 $1.85 Million
Q3 2022

Nov 14, 2022

SELL
$4.92 - $9.1 $1.2 Million - $2.21 Million
-242,936 Reduced 60.56%
158,206 $1.28 Million
Q2 2022

Aug 15, 2022

BUY
$4.2 - $24.0 $461,202 - $2.64 Million
109,810 Added 37.69%
401,142 $1.97 Million
Q1 2022

May 16, 2022

SELL
$9.96 - $23.65 $879,607 - $2.09 Million
-88,314 Reduced 23.26%
291,332 $4.97 Million
Q4 2021

Feb 14, 2022

BUY
$14.0 - $28.44 $3.47 Million - $7.05 Million
247,768 Added 187.88%
379,646 $5.97 Million
Q3 2021

Nov 12, 2021

BUY
$7.28 - $30.97 $115,366 - $490,781
15,847 Added 13.66%
131,878 $4.07 Million
Q2 2021

Aug 16, 2021

SELL
$8.09 - $12.0 $219,813 - $326,052
-27,171 Reduced 18.97%
116,031 $1.22 Million
Q1 2021

May 17, 2021

BUY
$10.94 - $15.32 $278,401 - $389,863
25,448 Added 21.61%
143,202 $1.69 Million
Q4 2020

Feb 16, 2021

BUY
$7.84 - $13.4 $529,968 - $905,813
67,598 Added 134.78%
117,754 $1.38 Million
Q3 2020

Nov 16, 2020

BUY
$7.22 - $20.7 $5,732 - $16,435
794 Added 1.61%
50,156 $397,000
Q2 2020

Aug 14, 2020

BUY
$9.11 - $22.06 $123,276 - $298,515
13,532 Added 37.77%
49,362 $902,000
Q1 2020

May 14, 2020

BUY
$9.49 - $21.26 $340,026 - $761,745
35,830 New
35,830 $427,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $156M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.